Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors

Inclusion Criteria: * Patients who have had hydatidiform mole treated by evacuation and/or curettage and now meet the criteria of low risk GTN, as defined by the International Federation of Gynecology and Obstetrics (F.I.G.O.)/World Health Organization (W.H.O.) 2002 staging and risk scoring criteria: * A plateau in the beta-hCG assay for 4 consecutive weekly levels over a period of 3 weeks or longer; that is, days 1, 7, 14, 21; for this study, a plateau will be defined as less than a 10% decline using as a reference the initial value in the series of values taken over a period of 3 weeks; OR * A rise in the beta-hCG assay of 3 consecutive measurements, or longer, over at least a period of 2 weeks or more; days, 1, 7, 14; for this study, a rise will be defined as an increase of greater than 20% taking as a reference the initial value in the series of values taken over the 2-week period; OR * When the beta-hCG level remains elevated above normal for 6 months or longer * Patients must have a clinically significant elevated beta-hCG level of greater than 20 mIU/ml * Patients must have non-metastatic low risk GTN with a W.H.O. 2002 risk score of no greater than 6 * Patients must have no metastatic disease as determined by the pelvic examination, pelvic ultrasound, and chest x-ray * Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization * Patients must have a Gynecologic Oncology Group (GOG) perfo…